Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C8H15N5O2.2ClH |
| Molecular Weight | 286.159 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.Cl.NNC1=CC=C(N=N1)N(CCO)CCO
InChI
InChIKey=UKFTXWKNVSVVCJ-UHFFFAOYSA-N
InChI=1S/C8H15N5O2.2ClH/c9-10-7-1-2-8(12-11-7)13(3-5-14)4-6-15;;/h1-2,14-15H,3-6,9H2,(H,10,11);2*1H
Oxdralazine is a peripheral vasodilator that was studied for patients with severe essential hypertension. The clinical trial has shown that at the end of the third month 25 patients on the triple regimen (chlorthalidone plus oxdralazine plus propranolol) achieved a stable diastolic blood pressure of 90 mm Hg or less. However, information about the further development of this drug is not available.
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Disposition and metabolism of 3-hydrazino-6-[N,N-bis(2-hydroxyethyl)amino] pyridazine dihydrochloride in man. | 1979 |
|
| Long-term study of oxdralazine in hypertensive patients. | 1979 |
|
| Metabolites of 3-hydrazino-6-[bis-(2-hydroxyethyl)amino]pyridazine dihydrochloride in rat urine. | 1979 |
|
| Synthesis of three metabolites of 3-hydrazino-6-[bis-(2-hydroxyethyl)amino]pyridazine. A new rearrangement of 3-[1-methylethyliden)hydrazino] derivative. | 1978-08 |
|
| Antihypertensive and antidiuretic effects of 3-hydrazino-6-[N, N-bis (2-hydroxyethyl) amino]-pyridazine (L 6150) in rats. | 1978-06 |
|
| Clinical and haemodynamic study of a new vasodilator drug L6150 (3-[bis-(2-hydroxyethyl)amino]-6-hydrazinopyridazine) in man. | 1976-12 |
|
| A comparative study of the hemodynamic effects of single intravenous doses of 3-hydrazino-6-[N,N-bis-(2-hydroxyethyl)-amino]-pyridazine-dihydrochloride and hydralazine. | 1976 |
|
| Systemic and coronary haemodynamic effects of the new hypotensive drug L 6150. | 1976 |
|
| Onthe pharmacology of 3-hydrazino-6-(N,N-bis(2-hydroxyethyl)amino)-pyridazine-dihydrochloride (L 6150). | 1973-11 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/7379444
Oxdralazine was given orally in doses of 15 to 30 mg to 7 subjects with hypertension
Route of Administration:
Oral
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Code | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
27464-23-9
Created by
admin on Mon Mar 31 21:52:43 GMT 2025 , Edited by admin on Mon Mar 31 21:52:43 GMT 2025
|
PRIMARY | |||
|
168701
Created by
admin on Mon Mar 31 21:52:43 GMT 2025 , Edited by admin on Mon Mar 31 21:52:43 GMT 2025
|
PRIMARY | |||
|
DTXSID60181884
Created by
admin on Mon Mar 31 21:52:43 GMT 2025 , Edited by admin on Mon Mar 31 21:52:43 GMT 2025
|
PRIMARY | |||
|
483KXL2L9D
Created by
admin on Mon Mar 31 21:52:43 GMT 2025 , Edited by admin on Mon Mar 31 21:52:43 GMT 2025
|
PRIMARY | |||
|
298268
Created by
admin on Mon Mar 31 21:52:43 GMT 2025 , Edited by admin on Mon Mar 31 21:52:43 GMT 2025
|
PRIMARY |
SUBSTANCE RECORD